Pacific Edge Ltd news

Pacific Edge is pleased to announce today that it has reached its first commercial agreement of scale in Australia with Northern Health, a major provider of healthcare and hospital services to Melbourne’s rapidly growing outer northern suburbs.

Northern Health provides healthcare services to the rapidly growing suburbs in Melbourne’s outer north through four campuses across the region, with over 5,700 professional staff. Northern Health’s urology needs make it s

Pacific Edge is pleased to report continuing growth for the six months ended 30 September 2021 (1H22), with key performance metrics significantly ahead of the same time last year, driven by reimbursement milestones, increasing insurance coverage and adoption by urologists and healthcare organisations.

Pacific Edge advises that its half year results for the six months ending 30 September 2021 will be released on Thursday 25 November 2021, prior to 10am.

This will be followed by an Investor and Analyst conference call at 10.30am (NZST). This investor briefing will be available via a webcast (presentation slides and audio only) or ‘audio only’ service. Please follow the instructions outlined below to access the event.

Pacific Edge has once again been named in the Deloitte Fast 50 Awards, as it continues to execute on its commercial strategy and drive revenue growth.

Pacific Edge was named 48th in the Fast 50 Index and the fastest growing export business for Dunedin and Lower South Island.

The company, which has recently completed a highly successful and well supported capital raise, is now well positioned to accelerate its growth, with recent commercial milestones, clinical validation and t

Pacific Edge today announces the appointment of Dr Peter Meintjes, an experienced molecular diagnostics and genomics business leader, as its new Chief Executive Officer.

Dr Meintjes, a New Zealand citizen currently resident in Boston, brings to Pacific Edge extensive global diagnostics, biotechnology, and commercial leadership expertise. He also has a track record for commercialising new and disruptive biotechnologies and driving rapid business growth across multiple territories inclu

Pacific Edge is pleased to announce it has successfully raised NZ$80 million (A$77.5 million¹) through its Placement.

The Placement was very well subscribed at the price determined in the bookbuild of NZ$1.35 (A$1.31) per share, resulting in Pacific Edge increasing the size of the Placement from NZ$60 million (A$58.1 million) to NZ$80 million (A$77.5 million).

The issue price of NZ$1.35 for the Placement was at the top of the bookbuild range and represents a 5.5% di

Cancer diagnostics company, Pacific Edge Limited (NZX: PEB) is pleased to announce that it has been admitted to the official list of the Australian Securities Exchange (ASX) as a foreign exempt listing and is conducting an equity raise consisting of a placement of NZ$60 million* (A$58.1 million ) with a Retail Offer of up to NZ$20 million (A$19.4 million) to eligible investors** to capitalise on recent commercial milestones and to accelerate the execution of its growth strategy in markets of

Pacific Edge Limited will today lodge an application with the Australian Stock Exchange (ASX) to dual list as a Foreign Exempt Entity. Subject to the ASX accepting the application, PEB expects to be dual-listed on the ASX by the end of September 2021.

Pacific Edge intends to maintain its primary listing on New Zealand Stock Exchange (NZX).

The Board believes that a dual listing on the ASX is a logical progression for the company and a way of accessing a broader pool of institu